Biomarkers as end points in clinical trials of severe sepsis: a garden of forking paths

Crit Care Med. 2010 Aug;38(8):1749-51. doi: 10.1097/CCM.0b013e3181e941f6.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Biomarkers / blood
  • Critical Care / standards
  • Critical Care / trends
  • Humans
  • Intensive Care Units
  • Interleukin-6 / blood*
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Sepsis / diagnosis*
  • Sepsis / drug therapy
  • Sepsis / mortality*
  • Sulfonamides / therapeutic use
  • Survival Rate
  • Treatment Outcome

Substances

  • Biomarkers
  • Interleukin-6
  • Sulfonamides
  • ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate